Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK573719 with Magnesium Stearate in COPD
NCT00732472Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any On-treatment Adverse Event (AE) or Any On-treatment Serious Adverse Event (SAE), Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 7 and 6 more. Started Oct 2008; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00732472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732472.